Sydney Medical School, Sydney Adventist Hospital Clinical School, University of Sydney, and Department of Urology, Sydney Adventist Hospital, Sydney, New South Wales, Australia.
There are few reports of the clinical outcomes of photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH) using the 120-W lithium triborate (LBO) laser. The present study evaluates clinical outcomes of 76 men treated with the 120-W LBO laser by an experienced PVP surgeon with 12 months follow up. The International Prostate Symptom Score (IPSS), peak flow rate (Qmax) and post-void residual (PVR) were examined at baseline and at 3 and 12 months. These parameters at baseline and 12 months were 20 ± 7.0, 7.6 ± 3.5 mL/s, 155 ± 155 mL and 8.1 ± 6.1, 22.5 ± 10.3 mL/s, 59 ± 87 mL, respectively. Clinically, meaningful improvements in IPSS, Qmax and PVR were observed at 3 months and sustained at 12 months. There were few adverse events, with only 5.3% of patients requiring recatheterization. Clinical outcome at 12 months was similar to that at 3 months and to other published series.
Written by:
Woo HH, Hossack TA. Are you the author?
Reference: Int J Urol. 2011 Feb;18(2):162-5.
doi: 10.1111/j.1442-2042.2010.02686.x
PubMed Abstract
PMID: 21272087
UroToday.com BPH and Male LUTS Section
